PubMed Health⌕ Search

Biomedical subjects

J Jespersen

Publications and source records attributed to J Jespersen.

At least 217 records · Page 12Linked to original sources
PubMed1983

Antithrombin III and platelets during the normal menstrual cycle and in women receiving oral contraceptives low in oestrogen.

Determinations of platelet number and concentration of antithrombin III (AT-III) were made in samples of plasma collected during one normal or hormone-simulated cycle in 14 young, normal women and in 11 women using an oral contraceptive low in oestrogen. Distinct, individual levels caused the variation of both parameters to be greater within the group than individually. Despite a few exceptions, a slight but statistically significant increase in the platelet number and AT-III level occurred around midcycle in the normal group. In the hormone group the platelet number increased slightly in the treatment period, while the AT-III level showed a corresponding slight decrease. The large decreases in AT-III levels reported by other authors testing oral contraceptives high in oestrogen were not seen in our study.

Adult↗
PubMed1983

Sequential study of plasma euglobulin fibrinolytic activity during the normal menstrual cycle and in women on oral contraceptives low in estrogen.

Determinations of plasma euglobulin fibrinolytic activity were made in samples of plasma collected during one normal or hormone-simulated cycle in 15 young, normal women and in 11 women using an oral contraceptive low in estrogen. Distinct, individual levels caused the variations of fibrinolytic activity to be larger within the group than individually, and the activity showed only small changes during the cycle. The hormone group showed a marked increase in fibrinolytic activity with distinct fluctuations related to the phase of the cycle. This increase corresponded to that previously reported to be caused by oral contraceptives containing higher concentrations of estrogen.

Adult↗
PubMed1982

Decreased levels of histidine-rich glycoprotein (HRG) and increased levels of free plasminogen in women on oral contraceptives low in estrogen.

Determinations by immunologic methods of histidine-rich glycoprotein (HRG) and plasminogen, were made in plasma samples collected during one normal or hormone induced cycle in 15 young, normal women and in 11 women using oral contraceptives with 30 micrograms ethinyl estradiol and 150 micrograms levo-norgestrel. The hormone group showed an increase in plasminogen level to about 150% of normal, while the concentration of HRG was decreased to about 75% of normal. This resulted in a considerable relative increase in the concentration of free plasminogen in the hormone group (calculated from the equilibrium: HRG . plasminogen in equilibrium HRG + plasminogen, using KD = 1.0 microM), representing a doubling of that in the normal group. Hence, more plasminogen is available for binding to fibrin and activation in the hormone group.

Adult↗
PubMed1982

A study of the conditions and accuracy of the thrombin time assay of plasma fibrinogen.

The conditions, accuracy, precision and possible error of the thrombin time assay of plasma fibrinogen are determined. Comparison with an estimation of clottable protein by absorbance at 280 nm gave a correlation coefficient of 0.96 and the regression line y = 1.00 x + 0.56 (n = 34). Comparison with a radial immunodiffusion method yielded the correlation coefficient 0.97 and the regression line y = 1.18 x = 2.47 (n = 26). The presence of heparin in clinically applied concentrations produced a slight shortening of the clotting times. The resulting error in the estimated concentrations of fibrinogen was too small to affect the clinical usefulness of the determinations. The influence of fibrin(ogen) degradation products was significant only in excessive amounts in samples containing low levels of fibrinogen.

Animals↗
PubMed1982

Individual levels of plasma histidine-rich glycoprotein (HRG) during the normal menstrual cycle and in women on oral contraceptives low in oestrogen.

Histidine-rich glycoprotein (HRG), a 3.8 S-alpha 2-glycoprotein recently identified as a new fibrinolysis regulating protein, was determined by an electroimmunoassay in samples of plasma collected during one menstrual or hormone cycle in 15 young women and in 11 women using oral contraceptives with 30 micrograms ethinyl oestradiol and 150 micrograms levo-norgestrel. Distinct individual levels caused the within-group variations of plasma HRG to be larger than the individual variations. In the hormone group the plasma HRG levels were decreased to about 75% of the normal, while the fluctuations during the cycle were minor in both groups.

Adult↗
PubMed1981

Post partum haemolytic-uraemic syndrome treated with antithrombin-III.

A 34-year-old woman with a family history of pregnancy-associated thrombotic disease developed pre-eclampsia in her 8th month of pregnancy. A severe haemolytic-uraemic syndrome (HUS) developed within 24 h after spontaneous delivery. Because the plasma antithrombin-III (AT-III) was only 15% of the normal concentration, an AT-III concentrate was given intravenously. When the normal level of plasma AT-III was reached, the clinical and biochemical signs of the syndrome disappeared. Renal function and biopsy were normal within 10 days. Because complete recovery is unusual in patients with post partum HUS and no previous reports have described a rapid recovery, the case reported here suggests that infusion of an AT-III concentrate should be tried when plasma AT-III is significantly decreased.

Adult↗
PubMed1981

Antithrombin-III and platelets in haemodialysis patients.

Plasma antithrombin-III (AT-III) levels in 18 patients on maintenance haemodialysis were studied. AT-III was measured functionally and immunologically before and after dialysis. Simultaneous counts of platelets were made. Prior to dialysis the average AT-III levels and platelet counts were found to be within the lower part of the normal range. On paired analysis the dialysis was seen to induce small, but significant decreases in AT-III levels and platelet counts. A positive linear correlation was found between levels of functionally and immunologically determined AT-III. Replacement of the intravenous application of heparin with an administration of low-dose, subcutaneous heparin is suggested.

Antithrombin III↗